A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Running, not enrolling · Phase 1

Conditions studied: Advanced Cancer

In brief

The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.

Key facts

Study ID

NCT06120075

Run by

Arcus Biosciences, Inc.

People needed

91

Starts

2024-01-19

Expected to finish

2026-11-01

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Denver, Colorado, United States
• Research Site — Washington D.C., District of Columbia, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — Grand Rapids, Michigan, United States
• Research Site — New York, New York, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Dallas, Texas, United States
• Research Site — San Antonio, Texas, United States
• Research Site — West Valley City, Utah, United States
• Research Site — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.